Japan’s Pharma Industry Proposes Plans To Reform Drug Pricing System
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The Japanese pharmaceutical industry has been in talks with the government over an industry proposal on ways to better sustain the price of novel drugs released in the country
You may also be interested in...
Global Pharmaceutical Outfits, While Closing Discovery Centers In Japan, Are Forging Alliances With Japanese Researchers (Part 3 Of 3)
Several multinational pharmaceutical companies have shut down their Japan-based discovery research facilities over the last few years. Some are relying more on discovery partnerships with local drug research entities in Japan. PharmAsia News' Tokyo bureau examines the factors behind the trend in this third article in a three-part series on the subject. Part one appeared in PharmAsia News on July 13, 2009, and part two appeared on July 20.
Global Pharmaceutical Outfits, While Closing Discovery Centers In Japan, Are Forging Alliances With Japanese Researchers (Part 3 Of 3)
Several multinational pharmaceutical companies have shut down their Japan-based discovery research facilities over the last few years. Some are relying more on discovery partnerships with local drug research entities in Japan. PharmAsia News' Tokyo bureau examines the factors behind the trend in this third article in a three-part series on the subject. Part one appeared in PharmAsia News on July 13, 2009, and part two appeared on July 20.
Japan's Medical Insurance Agency Considers Lowering Combo Drug Prices
Japan's Drug Pricing Committee of the Central Medical Insurance Agency [Chuikyo] considered a proposal July 15 to revise the current pricing formula for combination drugs, and some angiotensin II receptor blockers combined with diuretics could see prices lowered by as much as 30 percent in Japan